PureTech Health Plc Ingresos Q/Q
¿Qué es el Ingresos Q/Q de PureTech Health Plc?
El Ingresos Q/Q de PureTech Health Plc es -90.89%
¿Cuál es la definición de Ingresos Q/Q?
El crecimiento de los ingresos trimestrales, año tras año, es el aumento de los ingresos de una empresa en comparación con el compiortamiento en el trimestre correspondiente de un año anterior expresado como un porcentaje.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Ingresos Q/Q de compañías en Sector Health Care en LSE en comparadas con PureTech Health Plc
¿Qué hace PureTech Health Plc?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Empresas con ingresos q/q similar a PureTech Health Plc
- ContextLogic Inc tiene Ingresos Q/Q de -91.03%
- Royale Manor Hotels and Industries tiene Ingresos Q/Q de -90.99%
- Morien Resources tiene Ingresos Q/Q de -90.95%
- Nektan plc tiene Ingresos Q/Q de -90.92%
- NightFood tiene Ingresos Q/Q de -90.91%
- Mauria Udyog tiene Ingresos Q/Q de -90.90%
- PureTech Health Plc tiene Ingresos Q/Q de -90.89%
- Atenor SA tiene Ingresos Q/Q de -90.87%
- ATENOR SA tiene Ingresos Q/Q de -90.87%
- Radha Madhav tiene Ingresos Q/Q de -90.84%
- Hybrid Kinetic tiene Ingresos Q/Q de -90.82%
- Lambodhara Textiles tiene Ingresos Q/Q de -90.78%
- Enkei Wheels (India) tiene Ingresos Q/Q de -90.69%